Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more

Recent & Breaking News (NDAQ:IMUX)

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 3, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

PR Newswire October 27, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

PR Newswire October 20, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

PR Newswire October 10, 2022

Immunic to Participate in Scientific and Industry Conferences in October

PR Newswire October 4, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

PR Newswire September 20, 2022

Immunic, Inc. to Participate in Investor Conferences in September

PR Newswire September 1, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

PR Newswire August 16, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 4, 2022

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

PR Newswire August 2, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

PR Newswire July 28, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

PR Newswire July 6, 2022

Immunic to Participate in Industry and Scientific Conferences in July

PR Newswire June 28, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

PR Newswire June 15, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

PR Newswire June 8, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

PR Newswire June 2, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 10, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

PR Newswire May 5, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

PR Newswire May 3, 2022

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

PR Newswire April 25, 2022